Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile ALK fusion
Therapy Alectinib
Indication/Tumor Type Advanced Solid Tumor
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ALK fusion Advanced Solid Tumor predicted - sensitive Alectinib Phase II Actionable In a Phase II trial (TACKLE), Alecensa (alectinib) treatment demonstrated activity in adult and pediatric patients with advanced solid tumor harboring ALK fusions or rearrangements (n=17), resulting in an objective response rate (ORR) of 76.5% and disease control rate (DCR) of 82.4%, and median progression-free survival and median overall survival were not reached, and an ORR of 63.6% and DCR of 100% in pediatric patients younger than 15 years (J Clin Oncol 2025 43: 16_suppl, 5612). detail...
ALK fusion Advanced Solid Tumor predicted - sensitive Alectinib Phase Ib/II Actionable In a Phase I/II trial, Alecensa (alectinib) treatment resulted in 1 complete response, 3 partial responses, and 2 stable diseases in 7 evaluable pediatric patients with advanced solid tumors harboring ALK fusions with TPM3, CLTC, PLEKHA7, DCTN1, or HNRNPA3 (Cancer Res (2024) 84 (7_Supplement): CT039; NCT04774718). detail...
PubMed Id Reference Title Details
Abstract CT039: Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: Data from the iMATRIX Alectinib Phase I/II open-label, multi-center study Full reference...
Efficacy and safety of alectinib in pediatric and adult patients with ALK altered advanced solid tumors: Results from the TACKLE phase II trial, a MASTER KEY substudy (NCCH1712/MK003) Full reference...